Mestex Pharmaceutical Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Mestex Pharmaceutical General Information

Description

Operator of a biotech company engaged in developing innovative drug candidate MTX-071. The company's drug is an intra-articular injection of resiniferatoxin intended for the intra-articular treatment of pain associated with knee osteoarthritis.

Contact Information

Website
www.mestex.ch
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Klosterberg 11
  • 4051 Basel
  • Switzerland
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Grünenthal
Corporate Office
  • Klosterberg 11
  • 4051 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mestex Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mestex Pharmaceutical‘s full profile, request access.

Request a free trial

Mestex Pharmaceutical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech company engaged in developing innovative drug candidate MTX-071. The company's drug is an intra-ar
Biotechnology
Basel, Switzerland

Stockholm, Sweden
 

Burlington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mestex Pharmaceutical Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synartro Venture Capital-Backed Stockholm, Sweden
Bone Biologics Corporation Burlington, MA
You’re viewing 2 of 2 competitors. Get the full list »

Mestex Pharmaceutical Patents

  • 38

    Total Documents Applications and Grants

  • Total Patents Families

  • 19

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Mestex Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2880855-A1 Resiniferatoxin solution Inactive 03-Aug-2012
EP-2879660-A1 Resiniferatoxin solution Inactive 03-Aug-2012
US-20150190509-A1 Resiniferatoxin solution Inactive 03-Aug-2012
CA-2594203-A1 Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent Active 28-Dec-2004
ES-2533256-T3 Use of resiniferatoxin (rtx) for the manufacture of a medication for the treatment of pain Active 28-Dec-2004 A61K31/357
To view Mestex Pharmaceutical’s complete patent history, request access »

Mestex Pharmaceutical FAQs

  • Where is Mestex Pharmaceutical headquartered?

    Mestex Pharmaceutical is headquartered in Basel, Switzerland.

  • What industry is Mestex Pharmaceutical in?

    Mestex Pharmaceutical’s primary industry is Biotechnology.

  • Is Mestex Pharmaceutical a private or public company?

    Mestex Pharmaceutical is a Private company.

  • What is Mestex Pharmaceutical’s current revenue?

    The current revenue for Mestex Pharmaceutical is .

  • Who are Mestex Pharmaceutical’s competitors?

    Synartro and Bone Biologics are competitors of Mestex Pharmaceutical.

  • When was Mestex Pharmaceutical acquired?

    Mestex Pharmaceutical was acquired on 12-Apr-2021.

  • Who acquired Mestex Pharmaceutical?

    Mestex Pharmaceutical was acquired by Grünenthal.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »